Amylyx Pharmaceuticals

AMLX

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022.

Amylyx Pharmaceuticals has been a target of short sellers for a while. The current short interest of 11.43% is roughly at the average of the last 12 months (11.78%).